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Background: β-blockers are indicated as first-line therapy for patients with coronary artery disease (CAD), but the evidence supporting this 
recommendation predates the modern era of coronary revascularization. We therefore aimed to evaluate whether β-blockers affect angina or 
coronary events in CAD patients after revascularization.
methods: We performed a post-hoc analysis of the IMAGINE trial, which tested the effect of Quinapril in stable patients with LVEF > 40%, after 
scheduled CABG. The association between β-blockers, cardiovascular events (death, cardiac arrest, myocardial infarction, revascularization, angina, 
stroke or hospitalization for heart failure) and angina was tested with multivariate Cox regression analysis and a propensity matched analysis.
results: Of the 2232 patients randomized in IMAGINE, 1568 (70 %) received β-blocker therapy throughout follow-up. During a median follow up 
of 3 years, β-blockers were not associated with a reduction in the incidence of the composite endpoint (HR 1.06; CI 0.80-1.40) documented angina 
(HR 1.03; CI 0.77-1.39), or any other individual component of the composite endpoint. There were no relevant interactions among demographics, 
clinical history or surgical characteristic, including incomplete revascularizations. Propensity matching revealed similar results.
conclusions: These findings suggest that the efficacy of β-blockers is modest after coronary revascularization and argues against their 
indiscriminant use in these patients.
